In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Insight Molecular Diagnostics Inc (NASDAQ: IMDX) closed the day trading at $6.64 up 0.23% from the previous closing price of $6.62. In other words, the price has increased by $0.23 from its previous closing price. On the day, 50865.0 shares were traded. IMDX stock price reached its highest trading level at $7.1 during the session, while it also had its lowest trading level at $6.47.
Upgrades & Downgrades
In the most recent recommendation for this company, Lake Street on March 28, 2025, initiated with a Buy rating and assigned the stock a target price of $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 07 ’25 when James Andrea S. bought 97,561 shares for $2.05 per share. The transaction valued at 200,000 led to the insider holds 151,231 shares of the business.
SMITH PATRICK W bought 1,077,600 shares of IMDX for $2,209,080 on Feb 07 ’25. The 10% Owner now owns 2,872,671 shares after completing the transaction at $2.05 per share. On Feb 06 ’25, another insider, BROADWOOD PARTNERS, L.P., who serves as the 10% Owner of the company, bought 5,165,695 shares for $2.05 each. As a result, the insider paid 10,589,675 and bolstered with 11,410,100 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMDX now has a Market Capitalization of 190188544 and an Enterprise Value of 174623536. For the stock, the TTM Price-to-Sale (P/S) ratio is 43.22. Its current Enterprise Value per Revenue stands at 39.669 whereas that against EBITDA is -7.346.
Stock Price History:
The Beta on a monthly basis for IMDX is 1.35, which has changed by 2.1297169 over the last 52 weeks, in comparison to a change of 0.14725316 over the same period for the S&P500. Over the past 52 weeks, IMDX has reached a high of $8.51, while it has fallen to a 52-week low of $1.92. The 50-Day Moving Average of the stock is 5.40%, while the 200-Day Moving Average is calculated to be 64.85%.
Shares Statistics:
Over the past 3-months, IMDX traded about 69.91K shares per day on average, while over the past 10 days, IMDX traded about 42220 shares per day. A total of 28.63M shares are outstanding, with a floating share count of 24.96M. Insiders hold about 12.93% of the company’s shares, while institutions hold 56.84% stake in the company. Shares short for IMDX as of 1767139200 were 163199 with a Short Ratio of 2.33, compared to 1764288000 on 119330. Therefore, it implies a Short% of Shares Outstanding of 163199 and a Short% of Float of 1.2.
Earnings Estimates
. The current assessment of Insight Molecular Diagnostics Inc (IMDX) involves the perspectives of 1 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.18 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$1.15 and -$1.15 for the fiscal current year, implying an average EPS of -$1.15. EPS for the following year is -$1.0, with 1.0 analysts recommending between -$1.0 and -$1.0.
Revenue Estimates
4 analysts predict $285k in revenue. The current quarter. It ranges from a high estimate of $380k to a low estimate of $200k. As of. The current estimate, Insight Molecular Diagnostics Inc’s year-ago sales were $1.49MFor the next quarter, 4 analysts are estimating revenue of $522.8k. There is a high estimate of $810k for the next quarter, whereas the lowest estimate is $235.6k.
A total of 4 analysts have provided revenue estimates for IMDX’s current fiscal year. The highest revenue estimate was $3.3M, while the lowest revenue estimate was $3.2M, resulting in an average revenue estimate of $3.23M. In the same quarter a year ago, actual revenue was $1.88MBased on 4 analysts’ estimates, the company’s revenue will be $3.58M in the next fiscal year. The high estimate is $5.1M and the low estimate is $1.1M.
